ArticleFrontiers in oncology2025
Case Report: Primary extraskeletal osteosarcoma in prostate.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extraskeletal osteosarcoma (EOS) is an extremely uncommon malignant soft tissue sarcoma that carries a poor prognosis. However, EOS occurring in the prostate is especially rare. The purpose of this case report is to present the radiological features and immunohistochemistry results of the neoplasm in a 72-year-old man. In the case, contrast-enhanced CT and contrast-enhanced MRI clearly showed the primary lesion and the surrounding soft tissue invasion. In our case, massive calcification was seen within the tumor. Despite being regarded as a significant imaging symptom of EOS, calcification only happens in about half of the cases. In our case, positive immunohistochemistry results were included as follows: SATB2 (+), SMA (+), CD99 (+), CK (focal +), Ki-67 (+, hot spots about 40%), P63 (focal +), and Vim (+). Extensive resection is the preferred treatment method for localized lesions. Further adjuvant radiotherapy significantly decreased local recurrences, but chemotherapy did not decrease the risk of systemic recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.